STRENSIQ is a Subcutaneous Solution in the Human Prescription Drug category. It is labeled and distributed by Alexion Pharmaceuticals, Inc.. The primary component is Asfotase Alfa.
| Product ID | 25682-019_09d53de9-6c11-4f9f-9807-9141f9b7a91d |
| NDC | 25682-019 |
| Product Type | Human Prescription Drug |
| Proprietary Name | STRENSIQ |
| Generic Name | Asfotase Alfa |
| Dosage Form | Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2015-10-23 |
| Marketing Category | BLA / BLA |
| Application Number | BLA125513 |
| Labeler Name | Alexion Pharmaceuticals, Inc. |
| Substance Name | ASFOTASE ALFA |
| Active Ingredient Strength | 80 mg/.8mL |
| Pharm Classes | Alkaline Phosphatase [CS], Tissue-nonspecific Alkaline Phosphatase [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2015-10-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA125513 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2015-10-23 |
| Marketing Category | BLA |
| Application Number | BLA125513 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2015-10-23 |
| Ingredient | Strength |
|---|---|
| ASFOTASE ALFA | 80 mg/.8mL |
| SPL SET ID: | 3387574f-5eaa-4501-a71d-4cbfbd563031 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 25682-010 | STRENSIQ | ASFOTASE ALFA |
| 25682-013 | STRENSIQ | ASFOTASE ALFA |
| 25682-016 | STRENSIQ | ASFOTASE ALFA |
| 25682-019 | STRENSIQ | ASFOTASE ALFA |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() STRENSIQ 86105490 4874927 Live/Registered |
Alexion Pharmaceuticals, Inc. 2013-10-30 |